BURKITT’S LYMPHOMA WITH A PRIMARY LESION OF THE STOMACH (CLINICAL OBSERVATION)

The article describes the case of the primary stomach lymphoma of the stomach in a 29-year-old man. The literature data on the etiology, diagnosis and morphological characteristics of the primary lymphomas of the stomach are presented, the questions of treatment tactics, variants of cytostatic therapy schemes are touched upon.

In the described clinical example, the patient’s medical history is given: from the age of 16 the chronic gastroduodenitis is diagnosed, the patient periodically took omeprazole with a positive effect, there is no evidence of infection with Hp and there is no eradication. In April 2016, he noted the deterioration of health in the form of the appearance of discomfort in the epigastric region. In April 2016, an EHDS was performed at the outpatient stage, where an antral tumor of the stomach was detected, and a biopsy of the formation was taken. Histological examination of atypical cells was not revealed, and in connection with this, in May 2016, he was hospitalized at the A.M. Burnazyan for additional examination.

The article presents  data  of laboratory  and instrumental examination,  the  results  of EGDS, CT of thoracic  and abdominal  cavities, cytological, immunohistochemical,  and cytogenetic studies.

The patient  was given three courses of cytostatic  therapy. The first course of cytostatic  therapy was started  in June 2016, the patient  transferred it satisfactorily, in the post-cytostatic period there was a leukopenia of 2,5 thousand  cells/μl, against which the viral lesion of the tongue mucosa developed, and the therapy with virolex was performed with positive dynamics.

The EGD control showed marked positive dynamics. The second and third courses were conducted in July-August 2016, treatment was satisfactory. In September 2016 he was discharged for dynamic observation by a hematologist.

The article draws the attention of medical practitioners  to the fact that, in the absence of specific clinical manifestations, the basis for the diagnosis of lymphoma in this clinical example is the timely conduct of an endoscopic study with histological, immunohistochemical and cytogenetic  study of the biopsy.

1. Барях Е.А., Кравченко С.К., Обухова Т.Н., и соавт. Лимфома Беркитта: клиника, диагностика, лечение. Клин. Онкогематол. Фундаментальные исследования и клиническая практика. 2009; 2(2): 137-146. Baryakh E.A., Kravchenko S.K., Obukhova T.N. Burkitt’s Lymphoma: clinic, diagnostics, treatment. Clinical Oncohematol. Basic research and clinical practice. 2009; 2(2); 137-146 [in Russian].

2. Cамочатова Е.В., Островская А.В., Карачунский А.И. и др. Значение верификации варианта неходжкинских лимфом у детей для эффективности лечения по современным протоколам. Гематол. трасфузиол. 2000; 6: 9-14. Samochatova E.V., Ostrovskaya, A.V., Karachunskii A.I. The value of verification of the option of non-Hodgkin lymphoma in children for the treatment efficacy according to modern protocols. Hematol. transfusiol. 2000; 6: 9-14 [in Russian].

3. Тюкалова Н.P., Федоpова А.С., Шумилова И.В., Pумянцев А.Г. Неходжкинские лимфомы у детей: клиническая хаpактеpистика, возможности диагностики и теpапии; по данным клиник Pоссии и Белаpуси. Гематол. трансфузиол. 2002; 3: 58. Tyukalova N.P., Fedorov A.S., Shumilov V.I., Rumyantsev A.G. NonHodgkin’s lymphoma in children: clinical characteristics, diagnostics and therapeutics; according to the clinics of Russia and Belarus. Hematol. transfusiol. 2002; 3: 58 [in Russian].

4. Barnes J.A., Lacasce A.S., Feng Y. et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann. Oncol. 2011; 22(8): 1859-1864.

5. Eidt S., Stolte M., Fisher R. Helicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas. J. Clin. Pathol. 1994; 47: 436 –439.

6. Gossios K., Katsimbri P., Tsianos E. CT features of gastric lymphoma. Eur. Radiol. 2000; 10: 425–430.

7. Isaacson P.G. Helicobacter pilori_associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338: 1175–1176.

8. Isaacson P. Gastric MALT lymphoma: from concept to cure. Ann. Oncol. 1999; 10: 637, 645.

9. Kanda M., Ohshima K., Suzumiya J. et al. Follicular lymphoma of the stomach: immunohistochemical and molecular genetic studies. J. Gastroenterol. 2003; 38(6): 584-587.

10. Leonard J.P. Bortezomib plus CHOP — Rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 2010; 29(6); 690-697.

11. Link M.P., Shuster J.J., Donaldson S.S., et al. Treatment of children and young adults with early -stage non-Hodgkin lymphoma. NEJM. 1997; 337: 1259-1274.

12. Murphy S., Bowman W., Abromovitch M. et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B-cell (S Ig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J. Clin. Oncol. 1986; 4: 1732-1739.

13. Spreafico F., Massimino M., Luksch R, et al. Intensive, very short-term chemotherapy for advanced Burkitt’s lymphoma in children. J. Clin. Oncol. 2002; 20(12): 2783-2788. and therapeutics; according to the clinics of Russia and Belarus.